HOPE Therapeutics, Inc., a subsidiary of NRx Pharmaceuticals (NASDAQ: NRXP), has announced the acquisition of Kadima Neuropsychiatry Institute in La Jolla, California, a move set to enhance its nationwide network of psychiatric clinics. This acquisition is not only expected to bring profitability but also to be accretive to both revenue and EBITDA, signaling a robust expansion in the mental health care sector.
Dr. David Feifel, Kadima's founder and medical director, renowned for his leadership in interventional psychiatry, will join HOPE as Chief Medical Innovation Officer. This strategic addition underscores HOPE's commitment to integrating clinical care with cutting-edge research, particularly in treatments involving psychedelic medications and transcranial magnetic stimulation (TMS).
Kadima's role as a clinical template for HOPE's planned network is pivotal. The institute is celebrated for its comprehensive approach to treating conditions such as suicidal depression and PTSD, incorporating both traditional and innovative therapies. With HOPE targeting the acquisition of 30 clinics by the end of 2025 and projecting $100 million in annual revenue, this partnership exemplifies a significant stride towards addressing the growing demand for advanced mental health treatments.
NRx Pharmaceuticals' pipeline, including investigational drugs for suicidal bipolar depression and chronic pain, complements this expansion, highlighting the potential for groundbreaking advancements in psychiatric care. The acquisition of Kadima Neuropsychiatry Institute by HOPE Therapeutics represents a forward-looking approach to mental health care, promising to set new standards in treatment and research.
